



# Unique Microbial Catabolic Pathway for the Human Core *N*-Glycan Constituent Fucosyl- $\alpha$ -1,6-*N*-Acetylglucosamine-Asparagine

Jimmy E. Becerra,<sup>a</sup>  Jesús Rodríguez-Díaz,<sup>b</sup>  Roberto Gozalbo-Rovira,<sup>b</sup> Martina Palomino-Schätzlein,<sup>c</sup> Manuel Zúñiga,<sup>a</sup> Vicente Monedero,<sup>a</sup> María J. Yebra<sup>a</sup>

<sup>a</sup>Laboratorio de Bacterias Lácticas y Probióticos, Departamento de Biotecnología de Alimentos, IATA-CSIC, Paterna, Spain

<sup>b</sup>Departamento de Microbiología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain

<sup>c</sup>NMR Facility, Centro de Investigación Príncipe Felipe, Valencia, Spain

**ABSTRACT** The survival of commensal bacteria in the human gut partially depends on their ability to metabolize host-derived molecules. The use of the glycosidic moiety of *N*-glycoproteins by bacteria has been reported, but the role of *N*-glycopeptides or glycoamino acids as the substrates for bacterial growth has not been evaluated. We have identified in *Lactobacillus casei* strain BL23 a gene cluster (*alf-2*) involved in the catabolism of the glycoamino acid fucosyl- $\alpha$ -1,6-*N*-GlcNAc-Asn (6'FN-Asn), a constituent of the core-fucosylated structures of mammalian *N*-glycoproteins. The cluster consists of the genes *alfHC*, encoding a major facilitator superfamily (MFS) permease and the  $\alpha$ -L-fucosidase *AlfC*, and the divergently oriented *asdA* (aspartate 4-decarboxylase), *alfR2* (transcriptional regulator), *pepV* (peptidase), *asnA2* (glycosyl-asparaginase), and *sugK* (sugar kinase) genes. Knockout mutants showed that *alfH*, *alfC*, *asdA*, *asnA2*, and *sugK* are necessary for efficient 6'FN-Asn utilization. The *alf-2* genes are induced by 6'FN-Asn, but not by its glycan moiety, via the *AlfR2* regulator. The constitutive expression of *alf-2* genes in an *alfR2* strain allowed the metabolism of a variety of 6'-fucosyl-glycans. However, GlcNAc-Asn did not support growth in this mutant background, indicating that the presence of a 6'-fucose moiety is crucial for substrate transport via *AlfH*. Within bacteria, 6'FN-Asn is defucosylated by *AlfC*, generating GlcNAc-Asn. This glycoamino acid is processed by the glycosylasparaginase *AsnA2*. GlcNAc-Asn hydrolysis generates aspartate and GlcNAc, which is used as a fermentable source by *L. casei*. These data establish the existence in a commensal bacterial species of an exclusive metabolic pathway likely to scavenge human milk and mucosal fucosylated *N*-glycopeptides in the gastrointestinal tract.

**IMPORTANCE** The gastrointestinal tract accommodates more than 10<sup>14</sup> microorganisms that have an enormous impact on human health. The mechanisms enabling commensal bacteria and administered probiotics to colonize the gut remain largely unknown. The ability to utilize host-derived carbon and energy resources available at the mucosal surfaces may provide these bacteria with a competitive advantage in the gut. Here, we have identified in the commensal species *Lactobacillus casei* a novel metabolic pathway for the utilization of the glycoamino acid fucosyl- $\alpha$ -1,6-*N*-GlcNAc-Asn, which is present in the core-fucosylated *N*-glycoproteins from mammals. These results give insight into the molecular interactions between the host and commensal/probiotic bacteria and may help to devise new strategies to restore gut microbiota homeostasis in diseases associated with dysbiotic microbiota.

**KEYWORDS** *Lactobacillus casei*, alpha-L-fucosidase, core fucosylation, fucosylated *N*-glycopeptides, glycosylasparaginase

**Citation** Becerra JE, Rodríguez-Díaz J, Gozalbo-Rovira R, Palomino-Schätzlein M, Zúñiga M, Monedero V, Yebra MJ. 2020. Unique microbial catabolic pathway for the human core *N*-glycan constituent fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine. *mBio* 11: e02804-19. <https://doi.org/10.1128/mBio.02804-19>.

**Editor** Mark S. Turner, University of Queensland

**Copyright** © 2020 Becerra et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to María J. Yebra, [yebra@iata.csic.es](mailto:yebra@iata.csic.es).


**Received** 18 October 2019

**Accepted** 27 November 2019

**Published** 14 January 2020

Many investigations have recently highlighted the importance of the gut microbiota in the onset and progression of a number of human diseases, including gastrointestinal disorders (1, 2), inflammatory diseases (3), respiratory tract infections (4), and allergies (5). The functional impact of commensal gut microorganisms depends on their ability to survive in the gastrointestinal tract, adhere to epithelial mucus, and obtain energy from nondigestible dietary substrates and host mucosal secretions (6). More than half of all proteins in nature have been estimated to be glycosylated through *O*-glycosidic or *N*-glycosidic bonds (7). *O*-Glycans are linked to a serine or threonine residue via an *N*-acetylgalactosamine, which is elongated by additional sugars (8). *N*-Glycosylation is a common modification of extracellular membrane proteins present at the gastrointestinal epithelium, the secreted proteins of human breast milk, and many dietary proteins (7, 9–11). *N*-Linked glycans are attached via the core *N,N'*-diacetylchitobiose disaccharide (ChbNAc) (GlcNAc- $\beta$ 1,4-GlcNAc) to an asparagine residue of proteins containing the Asn-Xxx-Ser/Thr (with Xxx being any amino acid except Pro) motif (12). In *N*-glycans from mammals, the inner GlcNAc moiety bound to Asn is often fucosylated through an  $\alpha$ 1,6 linkage, named core fucose. Protein *N*-glycosylation plays a crucial role in a variety of cellular processes, such as cell adhesion (13), immune pathway signaling (14), and bacterial recognition (15). Some intestinal microorganisms have the ability to process the carbohydrate moieties of *N*-glycosylated proteins (16) so that the type, abundance, and location of these glycans contribute to shaping the composition and distribution of the gut microbiota (17). Some bacterial pathogens possess endo- $\beta$ -*N*-acetylglucosaminidase enzymes that cleave the  $\beta$ -1,4 linkage of the core ChbNAc present in all *N*-glycoproteins, releasing the *N*-glycan moiety (18). The activities of these enzymes have been associated with the modification of the biological function of host defense glycoproteins, such as immunoglobulins and lactoferrin (19–21), and with the use of the glycans as nutrients (21), for which they are considered virulence factors (22). In commensal bacteria, the ability to remove *N*-glycans from glycoproteins has been described in a few *Bifidobacterium* species (23, 24). Recently, the importance of core-fucosylated *N*-glycans from human milk in promoting the intestinal growth of *Bifidobacterium* and *Lactobacillus* species has been demonstrated in lactating infants from mothers carrying different alleles of the fucosyltransferase Fut8, responsible for core fucosylation (25). This provides the first *in vivo* evidence of the importance of this core structure in feeding intestinal commensals. However, there is little information about the fate of the fucosyl- $\alpha$ -1,6-GlcNAc bound to proteins through the Asn residue (6'FN-Asn). This glycoamino acid possibly results from the combined action of endo- $\beta$ -*N*-acetylglucosaminidase enzymes and proteases on *N*-glycosylated proteins (18, 23, 24). The amide bond between the amino acid and the GlcNAc residue is hydrolyzed by two different enzymes, peptide-*N*(4)-(β-*N*-acetylglucosaminy)-*L*-asparaginases (glycopeptide *N*-glycosidase) (PNGase) (EC 3.5.1.52) and *N*(4)-(β-*N*-acetylglucosaminy)-*L*-asparaginases (glycosylasparaginase) (EC 3.5.1.26). Both types of enzymes are produced as precursors that undergo intramolecular autolysis to produce the mature active proteins (26, 27), but PNGases require the presence of more than 2 amino acid residues in the substrate (28), whereas glycosylasparaginases act only in asparagine-oligosaccharides containing 1 amino acid (29). Currently, bacterial PNGases have been characterized only from the human pathogens *Elizabethkingia meningoseptica* and *Elizabethkingia miricola* (30, 31) and from the soil bacterium *Terriglobus roseus* (32). In *E. meningoseptica*, a glycosylasparaginase has also been characterized (33, 34).

*Lactobacillus casei* is a lactic acid bacterium able to survive in the gastrointestinal tract (35, 36), which has been isolated from a wide variety of habitats, including feces of breastfed infants (37, 38), and several strains are commonly used as probiotics in functional foods (39, 40). Oligosaccharides present in human milk, such as lacto-*N*-biose and *N*-acetyllactosamine, and derived from mucins, such as galacto-*N*-biose, can support the growth of *L. casei* (41, 42). This species is also able to catabolize lacto-*N*-triose (43) and fucosyl- $\alpha$ -1,3-*N*-acetylglucosamine (44), which are abundant carbohydrates that form part of larger glycan structures from human gut mucosae and human milk.




**FIG 1** (A) Structural organization of the *Lactobacillus casei* BL23 *alf-2* operon. (B) Schematic representation of the transport and catabolic pathways for fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine, fucosylated glycans (fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine, fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine, fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine, and fucosyl- $\alpha$ -1,6-*N,N'*-diacetylchitobiose), and fucosylated *N*-glycopeptides in *Lactobacillus casei*. AlfC,  $\alpha$ -L-fucosidase AlfC; AsnA2, *N*(4)-( $\beta$ -*N*-acetylglucosaminyl)-L-asparaginase; AsdA, aspartate 4-decarboxylase; PepV, peptidase V; SugK, sugar kinase.

Unlike glycans, catabolic pathways for *N*-glycopeptides in bacteria have not been described. In this work, we have identified in *L. casei* BL23 a gene cluster, named *alf-2*, involved in the metabolism of the glycoamino acid fucosyl- $\alpha$ -1,6-*N*-GlcNAc-Asn (6'FN-Asn). The results reported here have enabled us to propose a catabolic pathway for 6'FN-Asn and  $\alpha$ -1,6-fucosylated *N*-glycans in bacteria.


**RESULTS**

**Identification of the *L. casei alf-2* gene cluster involved in the metabolism of the glycoamino acid 6'FN-Asn.** We had previously shown that the disaccharide fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine (6'FN) is hydrolyzed *in vitro* by the *L. casei* BL23  $\alpha$ -L-fucosidase AlfC (glycosyl hydrolase family 29 [GH29]) (45). However, this bacterium is unable to grow in the presence of 6'FN as a carbon source (44). Analysis of the DNA region (GenBank accession no. FM177140) (46) around *alfC* revealed a gene cluster named here *alf-2* (Fig. 1A). This cluster consists of the genes *alfHC* (LCABL\_RS14345 and LCABL\_RS14350), which encode a major facilitator superfamily (MFS) permease and AlfC, respectively, and, divergently oriented, the genes *asdA* (LCABL\_RS14340), *alfR2*



**FIG 2**  $^1\text{H}$  NMR spectra of compounds in  $\text{D}_2\text{O}$  acquired at  $27^\circ\text{C}$  at 600 MHz with an inverse cryoprobe. (A) Fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn); (B) fucosyl- $\alpha$ -1,6-*N,N'*-diacetylchitobiose (N2F *N*-glycan); (C) fucosyl- $\alpha$ -1,6-galactose (6'FucGal); (D) fucosyl- $\alpha$ -1,6-glucose (6'FucGlc). Signals labeled with Fu correspond to copurified L-fucose.


(LCABL\_RS14335), *pepV* (LCABL\_RS14330), *asnA2* (LCABL\_RS14325), and *sugK* (LCABL\_RS14320). These genes encode proteins annotated as aspartate 4-decarboxylase (*asdA*), a GntR family transcriptional regulator (*alfR2*), peptidase M20 (*pepV*), *N*(4)-( $\beta$ -*N*-acetylglucosaminyl)-L-asparaginase (*asnA2*), and a ROK (repressor, open reading frame [ORF], kinase) family protein (*sugK*). Two putative *rho*-independent terminators were identified downstream of *alfC* ( $\Delta G$ ,  $-13.5$  kcal/mol) and *sugK* ( $\Delta G$ ,  $-17.0$  kcal/mol). The high specificity of the  $\alpha$ -L-fucosidase AlfC from *L. casei* BL23 for  $\alpha$ 1,6 linkages such as those present at fucosyl-oligosaccharides (45, 47), together with the sequence analysis of the *alf-2* cluster, particularly the presence of a gene coding for a hypothetical *N*(4)-( $\beta$ -*N*-acetylglucosaminyl)-L-asparaginase, suggested that the *alf-2* operon could be involved in the metabolism of the core 6'FN-Asn (Fig. 1). To test this hypothesis, this glycoamino acid was synthesized by transglycosylation with the  $\alpha$ -L-fucosidase AlfC. We had previously utilized AlfC in transglycosylation reactions with *p*-nitrophenyl- $\alpha$ -L-fucopyranoside (*p*NP-fuc) as the donor and GlcNAc as the acceptor to produce 6'FN (47). Here, the ability of AlfC to use GlcNAc-Asn as the acceptor was tested, and 6'FN-Asn was synthesized and purified. The purified 6'FN-Asn was characterized by nuclear magnetic resonance (NMR) spectroscopy (Fig. 2A) (see Fig. S1 and Table S1 in the supplemental material). ChbNAc, galactose, and glucose were also used in transglycosylation reactions with AlfC, and the glycans fucosyl- $\alpha$ -1,6-*N,N'*-diacetylchitobiose



**FIG 3** Growth profiles of *Lactobacillus casei* on *N*-glycan derivatives. (A and B) *L. casei* wild-type strain BL23 (A) and strain BL405, an *alfr2* deletion mutant (B), grown on MRS basal medium without a carbon source or with fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn), fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine (6'FN), *N*-acetylglucosamine-asparagine (GlcNAc-Asn), fucosyl- $\alpha$ -1,6-glucose (6'FucGlc), fucosyl- $\alpha$ -1,6-galactose (6'FucGal), or fucosyl- $\alpha$ -1,6-*N,N'*-diacetylchitobiose (N2F *N*-glycan). (C) HPLC chromatograms (Dionex system) of the standard compounds L-fucose (0.25 mM) (chromatogram 1), 6'FN (0.2 mM) (chromatogram 2), N2F *N*-glycan (0.2 mM) (chromatogram 3), 6'FucGlc (0.2 mM) (chromatogram 4), and 6'FucGal (0.2 mM) (chromatogram 5) and culture supernatants (diluted 20 times) from *L. casei* BL23 (WT) (chromatograms 6, 8, 10, 12, and 14) and BL405 (*alfr2*) (chromatograms 7, 9, 11, 13, and 15) grown in 6'FN (chromatograms 6 and 7), 6'FucGlc (chromatograms 8 and 9), 6'FucGal (chromatograms 10 and 11), or N2F *N*-glycan (chromatograms 12 and 13) or without sugar (chromatograms 14 and 15). The numbers by the L-fucose peaks indicate the concentration (millimolar). nC, nanoCoulomb.

(N2F *N*-glycan), which forms part of the core fucosylation; fucosyl- $\alpha$ -1,6-galactose (6'FucGal); and fucosyl- $\alpha$ -1,6-glucose (6'FucGlc) were also synthesized (Fig. 2B to D and Table S1).

To determine whether *L. casei* BL23 is able to use 6'FN-Asn, GlcNAc-Asn, N2F *N*-glycan, 6'FucGal, or 6'FucGlc as a carbon source, its growth profiles in MRS basal medium supplemented with each compound were analyzed. *L. casei* grew only in the presence of the glycoamino acid 6'FN-Asn (Fig. 3A). The analysis of the carbohydrate content of the growth medium showed that BL23 did not degrade any of the assayed glycans (Fig. 3C). However, the *Alfr2*-deficient strain (BL405) could degrade all the synthesized 6'-fucosyl oligosaccharides, as evidenced by the quantitative accumulation of L-fucose in the supernatant and the disappearance of the peaks corresponding to the fucosylated substrates (Fig. 3C). The presence of L-fucose in the culture supernatants




**FIG 4** Expression of *alf-2* genes in *Lactobacillus casei*. *L. casei* BL23 (WT) and *L. casei* BL405 (*alfR2* deletion mutant) were grown in MRS basal medium containing fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn), fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine (6'FN), or *N*-acetylglucosamine (GlcNAc). Gene expression in *L. casei* BL405 in the presence of glucose is also shown. Expression was monitored by RT-qPCR, and *L. casei* BL23 (WT) cells grown in MRS basal medium with glucose were used as a reference. Data presented are mean values based on at least three replicates. Bars indicate standard errors.

was due to the fact that *L. casei* does not metabolize L-fucose and excretes it into the culture medium (44). Nevertheless, growth with these carbon sources was very poor compared to that with 6'FN-Asn (Fig. 3B). Interestingly, like the wild type (WT), the *alfR2* mutant strain did not use GlcNAc-Asn (Fig. 3B). These results suggested that *AlfR2* represses the expression of *alf-2* genes and that the presence of 6'FN-Asn is required to relieve repression. Furthermore, the existence of an L-fucose moiety with an  $\alpha$ 1,6 linkage configuration is possibly necessary for the uptake of the tested fucosyl oligosaccharides, including 6'FN-Asn.

**Transcription of the *alf-2* gene cluster is induced by 6'FN-Asn and repressed by *AlfR2*.** To find out whether the transcription of the *alf-2* genes is regulated by the glycoamino acid 6'FN-Asn or its glycan moiety, reverse transcription-quantitative PCR (RT-qPCR) experiments were performed with RNA isolated from *L. casei* BL23 grown with 6'FN-Asn, 6'FN, GlcNAc, or glucose (Fig. 4). The results showed that the *alf-2* operon is induced by the glycoamino acid 6'FN-Asn and not by the presence of 6'FN or GlcNAc, indicating that the glycoamino acid and not the glycan moiety is responsible for the induction of these genes and explaining the lack of growth of the wild type on N2F *N*-glycan, 6'FucGal, and 6'FucGlc. In order to obtain direct evidence for the regulation of *AlfR2* on these genes, RNA was isolated from the *alfR2* deletion strain BL405 cultured under the same conditions as those for the wild type (Fig. 4). Regardless of the substrate tested, the expression levels of *alf-2* genes were higher than those in the wild type growing on glucose, indicating that *AlfR2* indeed acts as a transcriptional repressor.

**The *AlfC*  $\alpha$ -L-fucosidase and the *AlfH* permease are necessary for the metabolism of 6'FN-Asn and 6'-fucosyl-oligosaccharides.** To assess the role of *alfC* and *alfH* in the catabolism of 6'FN-Asn in *L. casei*, the growth patterns of mutant strains disrupted in *alfC* (BL415) and *alfH* (BL372) were analyzed in MRS basal medium supplemented with the fucosylated glycoamino acid (Fig. 5A and B). The profiles showed that both mutants failed to grow on 6'FN-Asn. To further confirm that the glycoamino acid was not fermented, culture supernatant analyses were performed, and they showed that 6'FN-Asn remained in BL415 and BL372 supernatants, without the appearance of L-fucose (Fig. 5E). The amount of L-fucose (1.12 mM) present in both supernatants corresponded to the amount of L-fucose copurified with the synthesized 6'FN-Asn (Fig. 2 and Fig. 5E). These results demonstrated that the  $\alpha$ -L-fucosidase *AlfC*



**FIG 5** Growth curves of *Lactobacillus casei* mutant strains. (A and B) BL415 (*alfC*) (A) and BL372 (*alfH*) (B) on MRS basal medium without a carbon source or with fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn) or *N*-acetylglucosamine (GlcNAc). (C and D) BL406 (*alfR2 alfC*) (C) and BL407 (*alfR2 alfH*) (D) on MRS basal medium without a carbon source or with fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn), *N*-acetylglucosamine (GlcNAc), 6'FN, 6'FucGlc, 6'FucGal, or N2F *N*-glycan. (E) HPLC chromatograms of mutant strains and their growth media. (Continued on next page)

is involved in the metabolism of 6'FN-Asn and that the permease AlfH participates in its transport. To determine the role of AlfC and AlfH in the utilization of the rest of the fucosyl-glycans synthesized here (6'FN, 6'FucGlc, 6'FucGal, and N2F *N*-glycan), two double mutant strains, BL406 (*alfR2 alfC*) and BL407 (*alfR2 alfH*), were constructed. Both mutants showed growth patterns with 6'-fucosyl-glycans similar to that of the negative-control culture without an added carbohydrate (Fig. 5C and D). In addition, the results showed a final culture optical density (OD) of strain BL406 or BL407 that was significantly lower than that of strain BL405 (*alfR2*) on these sugars (Table S2). These results indicated that the  $\alpha$ -L-fucosidase AlfC and the permease AlfH are also involved in their metabolism and transport, respectively. 6'FN-Asn was also tested as a carbon source in the culture medium with these double mutants, confirming the requirement of a functional  $\alpha$ -L-fucosidase and permease for its metabolism (Fig. 5C and D).


**6'FN-Asn catabolism requires AsdA, AsnA2, and SugK but not PepV.** An *asdA* mutant strain (BL416) showed impaired growth in MRS basal medium supplemented with 6'FN-Asn (Fig. 6A). Curiously, the glycoamino acid was completely depleted from the culture supernatant (Fig. 5E); however, the mutant strain reached a lower optical density than the wild-type strain, suggesting that *asdA* is involved in 6'FN-Asn metabolism. A BLAST search using the deduced amino acid sequence of AsdA against the genomic sequence of *L. casei* BL23 did not reveal the presence of other AsdA paralogues. AsdA belongs to the Asp aminotransferase family (cd00609), which also includes a number of enzymes with decarboxylase or racemase activities. The BL23 genome encoded 11 hypothetical carboxylases ([https://www.ncbi.nlm.nih.gov/genome/proteins/652?genome\\_assembly\\_id=300266](https://www.ncbi.nlm.nih.gov/genome/proteins/652?genome_assembly_id=300266)); whether AsdA is a decarboxylase and whether any of these enzymes would complement its activity need to be investigated. A *pepV* mutant strain (BL417) showed a growth pattern similar to that of the wild-type strain (Fig. 6B), indicating that the hypothetical peptidase encoded by this gene is not essential for the metabolism of 6'FN-Asn. The two genes *asnA2* and *sugK*, present downstream of *pepV*, were, however, necessary for the utilization of 6'FN-Asn by *L. casei*. An *asnA2* (BL418) mutant strain constructed here and a *sugK* (BL392) mutant characterized previously (41) failed to grow on 6'FN-Asn (Fig. 6C and D). These results indicate that both the putative glycosylasparaginase AsnA2 and the putative sugar kinase SugK are required for the catabolism of 6'FN-Asn.

**AsnA2 has glycosylasparaginase activity.** The capacity to catabolize 6'FN-Asn by *L. casei* indicated that AsnA2 probably encodes a glycosylasparaginase that would cleave the linkage between GlcNAc and Asn. To confirm this hypothesis, AsnA2 was overexpressed as a His-tagged protein and purified (Fig. S2). The molecular weight of His-tagged AsnA2 was estimated to be 55.6 kDa using size exclusion chromatography, which does not coincide with the theoretical molecular mass (36.071 kDa), suggesting that the enzyme probably forms dimers. Interestingly, when the purified AsnA2 fraction was subjected to SDS-PAGE analysis, three bands were observed: a very faint band at about 38.0 kDa and two other bands with estimated molecular weights of 18.2 and 17.8 kDa. Mass spectrometry (MS) analysis showed that all three protein bands were derived from the glycosylasparaginase AsnA2 (data not shown). The 38-kDa band corresponds to the full-length protein, whereas the 18.2- and 17.8-kDa fragments correspond to the N-terminal and C-terminal domains, respectively. Therefore, AsnA2 is probably a zymogen that is processed during purification. A mechanism of intramo-

#### FIG 5 Legend (Continued)

(*alfR2 alfH*) (D) on MRS basal medium without a carbon source or with 6'FN-Asn, fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine (6'FN), fucosyl- $\alpha$ -1,6-glucose (6'FucGlc), fucosyl- $\alpha$ -1,6-galactose (6'FucGal), fucosyl- $\alpha$ -1,6-*N,N'*-diacetylchitobiose (N2F *N*-glycan), or GlcNAc. The four mutant strains were grown in MRS basal medium with GlcNAc as a positive control. (E) HPLC chromatograms (Dionex system) of the supernatants (diluted 10 times) from *Lactobacillus casei* strain cultures. Shown are chromatograms of the standards L-fucose (0.4 mM) (chromatogram 1), GlcNAc (0.1 mM) (chromatogram 2), *N*-acetylglucosamine-asparagine (GlcNAc-Asn) (0.1 mM) (chromatogram 3), and 6'FN-Asn (0.1 mM) (chromatogram 4). Also shown are chromatograms of the culture supernatants from *L. casei* BL23 (WT) cultured without added sugar (chromatogram 5) or from *L. casei* strains cultured on 6'FN-Asn, including BL23 (WT) (chromatogram 6), BL418 (*asnA2*) (chromatogram 7), BL417 (*pepV*) (chromatogram 8), BL416 (*asdA*) (chromatogram 9), BL415 (*alfC*) (chromatogram 10), BL372 (*alfH*) (chromatogram 11), BL392 (*sugK*) (chromatogram 12), and BL405 (*alfR2*) (chromatogram 13). The numbers by the L-fucose peaks indicate the concentration (millimolar). nC, nanoCoulomb.





**FIG 6** Growth curves of *Lactobacillus casei* mutant strains. Shown are growth curves for BL416 (*asdA*) (A), BL417 (*pepV*) (B), BL418 (*asnA2*) (C), and BL392 (*sugK*) (D) on MRS basal medium without a carbon source or with fucosyl- $\alpha$ -1,6-*N*-acetylglucosamine-asparagine (6'FN-Asn) or *N*-acetylglucosamine (GlcNAc). In all graphs, the growth pattern of wild-type (WT) strain BL23 is presented for a better comparison.

lecular autoproteolysis has been previously described for glycosylasparaginases and PNGases (26, 27). The self-processing of the precursor protein occurs at a Thr residue, and the two fragments form a noncovalent heterodimeric complex (26). A BLAST search with the amino acid sequence of *L. casei* AsnA2 evidenced 28% sequence identity to the glycosylasparaginase of *E. meningoseptica* (26). The sequence alignment between both proteins revealed that all residues involved in autoproteolytic processing, including the catalytic Thr residue (Thr-154 in AsnA2), are conserved. We analyzed the activity of the purified AsnA2 by measuring the release of GlcNAc from GlcNAc-Asn, which confirmed that AsnA2 is an *N*(4)-( $\beta$ -*N*-acetylglucosaminyl)-*L*-asparaginase (Fig. S2). This exhibited a specific activity of  $20.91 \mu\text{mol mg protein}^{-1} \text{min}^{-1}$  for GlcNAc-Asn. The activity of AsnA2 on the fucosylated glycoamino acid was also tested (Fig. S2). In contrast to the human glycosylasparaginase, which does not act on 6'FN-Asn (48), AsnA2 was able to degrade 6'FN-Asn, releasing 6'FN with a specific activity of  $0.26 \mu\text{mol mg protein}^{-1} \text{min}^{-1}$ . These results indicated that AsnA2 preferentially acts on GlcNAc-Asn over the fucosylated substrate 6'FN-Asn.

**AsdA displays aspartate 4-decarboxylase activity, and SugK displays kinase activity.** As described below, the Asp resulting from the activity of AsnA2 on GlcNAc-Asn might be the substrate for the AsdA enzyme. To test this hypothesis, AsdA was overexpressed with a His tag and purified. Recombinant AsdA showed decarboxylation activity on *L*-Asp, with a specific activity of  $10.97 \pm 2.27 \text{ nmol mg protein}^{-1} \text{min}^{-1}$ . This weak activity on *L*-Asp might indicate that this amino acid is not the preferred substrate for AsdA. Regarding SugK, the proposed pathways for 6'FN-Asn and 6'-fucosyl-glycans (Fig. 1B) involved the release of the monosaccharides GlcNAc, Glc, and Gal, which should be phosphorylated by specific kinases before entering glycolysis. In order to

prove whether SugK showed kinase activity on these sugars, it was overexpressed as a His-tagged protein and purified. SugK displayed kinase activity on GlcNAc ( $1.44 \mu\text{mol mg protein}^{-1} \text{min}^{-1}$ ) but could not phosphorylate Glc and Gal. Activity on *N*-acetylgalactosamine (GalNAc) was also assayed, as this *N*-acetylhexosamine is also very abundant on mucosa-associated glycans, and no activity on this sugar was detected.

**Proposed pathway for 6'FN-Asn catabolism in *L. casei*.** The genetic and biochemical evidence reported here allows the proposal of a catabolic pathway for 6'FN-Asn in *L. casei* (Fig. 1B). The glycoamino acid is internalized by the permease AlfH, which has broad specificity over a range of 6'-fucosylated substrates, and is subsequently defucosylated by the  $\alpha$ -L-fucosidase AlfC, generating L-fucose and GlcNAc-Asn. The released L-fucose is excreted from the cells by an as-yet-undetermined mechanism, while GlcNAc-Asn is split by AsnA2 into Asp and 1-amino-GlcNAc, which is unstable, and it is nonenzymatically converted to GlcNAc and ammonium (49, 50). The requirement of AlfC for 6'FN-Asn utilization and the lower affinity of AsnA2 for 6'FN-Asn than for GlcNAc-Asn support that the catabolism of 6'FN-Asn occurs through the consecutive actions of AlfC and AsnA2. GlcNAc produced by the action of AsnA2 on GlcNAc-Asn would then be the substrate for the sugar kinase SugK (Fig. 1). The other resulting product of AsnA2 activity, Asp, might be the substrate of AsdA, although the weak aspartate 4-decarboxylase activity could indicate that AsdA may play an as-yet-undetermined role in this pathway. Regarding the function of *pepV*, which encodes a putative peptidase, no signal peptide was evidenced for it, suggesting that it is a cytoplasmic protein. The permease AlfH might also transport more complex substrates, like *N*-glycosylated peptides derived from the proteolysis of host- and food-derived proteins. Furthermore, the fact that AlfC is able to release L-fucose from core fucosylation of the Fc fragment from immunoglobulins (51) shows that this enzyme has the capacity to hydrolyze  $\alpha$ -1,6 linkages in polypeptidic substrates and could act on core-fucosylated *N*-glycopeptides. In this case, after the release of L-fucose by AlfC, amino acids would be removed by *PepV* to liberate GlcNAc-Asn (Fig. 1B).

## DISCUSSION

*N*-Glycosylated proteins are present at human mucosal surfaces and in breast milk (9, 10, 52), and therefore, they can be accessible to the gut microbiota. Most studies about energy sources for gut-beneficial microbes have been focused on carbohydrates present in the diet or added as prebiotics (53), whereas knowledge about the catabolism of host-derived carbon and nitrogen sources is scarce (16). We have demonstrated that *L. casei* is able to metabolize the glycoamino acid 6'FN-Asn, which is the core structure of the *N*-glycan sites of  $\alpha$ 1,6-fucosylated glycoproteins. The relevance of the metabolism of this core structure for intestinal microbial ecology was recently established *in vivo* in humans and in mouse models with reduced  $\alpha$ 1,6-fucosylation of core structures (25). In this work, we filled the existing gap relative to the metabolic pathways involved in the utilization of core-fucosylated *N*-glycopeptides by bacteria. The backbone of the *L. casei* 6'FN-Asn pathway consists of the MFS transporter AlfH; the  $\alpha$ -L-fucosidase AlfC, which removes the  $\alpha$ 1,6-fucosyl residue; and the glycosylasparaginase AsnA2, which processes the resulting GlcNAc-Asn to 1-amino-GlcNAc and Asp (Fig. 1B). The generated 1-amino-GlcNAc is not metabolizable, but this compound is unstable at acidic pH, and it degrades into GlcNAc and ammonium (49). As lactobacilli do not maintain a constant internal pH, but it decreases as the external pH drops (54), intracellular conditions may allow the spontaneous degradation of 1-amino-GlcNAc. The resulting GlcNAc would then be the substrate for the sugar kinase SugK, allowing its channeling through glycolysis.

The genetic organization of the *L. casei* *alf-2* gene cluster is well conserved in gene content and gene order across the *L. casei*-*Lactobacillus paracasei*-*Lactobacillus rhamnosus* phylogenetically related group of lactobacilli, excepting the absence of *asdA* in *L. rhamnosus* (Fig. 7). Homologues of *alfC* are present in only a few *Lactobacillus* species, and the closest homologues are harbored by some bifidobacteria isolated from Hyme-



**FIG 7** Structural organization of the *alf-2* gene clusters from *Lactobacillus rhamnosus* GG, *Lactobacillus heilongjiangensis* DSM 28069, *Lactobacillus nantensis* DSM 16982, *Lactobacillus melliventris* Hma8, *Bifidobacterium asteroides* Bin2, *Bifidobacterium actinocoloniiforme* DSM 22766, *Lactobacillus manihotivorans* DSM 13343, *Lactobacillus gasseri* ATCC 33323, *Lactobacillus johnsonii* ATCC 33200, *Lactobacillus curvatus* MRS6, and *Lactobacillus sakei* LS25. Stem-loop structures in *L. casei* DNA represent putative *rho*-independent terminators. Surrounding genes near the *alf-2* genes are also shown. The organization of the *Lactobacillus casei* BL23 *alf-2* operon is also shown for a better comparison. PTS, phosphotransferase system.

noptera (55–57) (see Fig. S3A in the supplemental material). Interestingly, many lactobacilli carrying *alfC* have also been isolated from insects (58, 59). Phylogenetic analyses of these genes show that they constitute a well-supported cluster together with the *alfC* gene of *Vagococcus humatus*. More distant homologues are mostly present in gut anaerobic bacteria (Fig. S3A). Homologues of *L. casei alfH* are mostly found in the same set of species, although this gene is also present in other bifidobacteria and in *Lactobacillus kisonensis* (Fig. S3B). The genetic association of these genes in these species and their close phylogenetic relationships suggest that they share an origin and an evolutionary history. Homologues of *AsnA2* (Fig. S4), *AsdA* (Fig. S5), and *PepV* (Fig. S6) are present in numerous lactobacilli. Indeed, *Lactobacillus gasseri* ATCC 33323, which carries a gene cluster with *asnA2*, *pepV*, and *alfR2* (Fig. 7), was recently shown to grow with 6'FN and N2F *N*-glycan (25). However, in the same work, *L. casei* ATCC 334 was reported to use L-fucose, which is contradictory to the fact that no *fuc* genes are present in its genome (60). In addition, *L. casei* ATCC 334 was also shown to metabolize 6'FN and N2F *N*-glycan (25), which, according to our results with *L. casei* BL23, can be possible only if the repressor *alfR2* is inactivated.

In bifidobacteria, *AsnA2* homologues are present only in *Bifidobacterium actinocoloniiforme*, *Bifidobacterium asteroides*, and *Bifidobacterium xylocopae* (Fig. S4), and as for their *AlfC* and *AlfH* counterparts, they are most closely related to *Lactobacillus* sequences. The limited presence in bifidobacteria and the phylogenetic clustering of the three bifidobacterial genes within *Lactobacillus* sequences suggest that they were transferred from *Lactobacillus* to *Bifidobacterium*. Genes encoding *PepV* homologues are absent in bifidobacteria, whereas *asdA* genes have been detected only in *Bifidobacterium magnum* and *Bifidobacterium gallicum*. The *AsdA* bifidobacterial sequences constitute a well-supported cluster with sequences from the *Bacteroidetes* and are not closely related to their *Lactobacillus* counterparts (Fig. S5), indicating that they had a different evolutionary origin. Interestingly, the closest relatives of *L. casei pepV* are genetically linked to *asnA2* homologues (Fig. 7). This observation suggests a functional link between *PepV* and *AsnA2*.

Glycosylasparaginases (EC 3.5.1.26) are essential for the removal of the sugar moiety from the Asn in the GlcNAc-Asn structures derived from *N*-glycoproteins in humans (29, 61). These enzymes cleave the  $\beta$ -aspartylglucosamine linkage, and they require both a free  $\alpha$ -amino and  $\alpha$ -carboxy group on the Asn substrate (29). In lactobacilli, an *asnA2* homologue had been previously identified in *Lactobacillus sakei* as a gene induced during meat (sausage) fermentation, and a knockout mutant resulted in reduced growth on meat, but its activity was not ascertained (62). In contrast to the *Elizabethkingia* glycosylasparaginase, *AsnA2* from *L. casei* characterized here lacks a signal peptide, strongly suggesting that it is an intracellular enzyme. As described above for glycosylasparaginases, *AsnA2* suffers a self-processing proteolytic process to render an active enzyme (Fig. S2). The mature *AsnA2* enzyme did not show activity on glycosylated proteins (Fig. S2D), but it showed *in vitro* activity on 6'-fucosylated and nonfucosylated GlcNAc-Asn. Curiously, the presence of the linked L-fucose blocks the hydrolysis of 6'FN-Asn by the human glycosylasparaginase (29). However, for the related PNGases, it has been demonstrated that the size of the carbohydrate moiety in the substrate has little effect on their activity (63). Therefore, *AsnA2* would exhibit intermediate characteristics between both types of enzymes:  $\alpha$ -1,6-linked L-fucose does not block hydrolysis, and the enzyme does not require a glycosylated peptide as the substrate.

We previously characterized the  $\alpha$ -L-fucosidase *AlfC* from *L. casei* (45) and demonstrated that it displays high regiospecific transglycosylation activity that produces 6'FN disaccharide (47). This enzyme constitutes the only characterized bacterial  $\alpha$ -L-fucosidase acting on  $\alpha$ -1,6 linkages in core fucosylation structures (core fucosidase), and it was recently employed as a tool for IgG glycoengineering to obtain defucosylated immunoglobulins with enhanced antibody cell-mediated toxicity (51). Core fucosylation of *N*-glycopeptides and *N*-glycoproteins has also been attained using *L. casei* *AlfC* mutant enzymes (64). In addition to GlcNAc, we show here that *AlfC* is able to use

GlcNAc-Asn, ChbNAC, galactose, and glucose as acceptor substrates in transfucosylation reactions. All the synthesized compounds (6'FN-Asn, N2F *N*-glycan, 6'FucGal, and 6'FucGlc) have exclusively  $\alpha$ -1,6-fucosidic bonds, confirming the high linkage specificity of AlfC. However, the recognition of different acceptors indicates a relaxed substrate specificity.

Wild-type *L. casei* did not metabolize the 6'-fucosyl-glycans 6'FN, N2F *N*-glycan, 6'FucGal, and 6'FucGlc, probably due, as shown for 6'FN, to their inability to induce the *alf-2* operon. This was confirmed by inactivating *alfR2*, which resulted in the constitutive expression of *alf-2* genes and the subsequent catabolism of these oligosaccharides. Although *alf-2* operon induction required the complete glycoamino acid 6'FN-Asn, the coexistence of this and other 6'-fucosyl-glycans in environments such as the gastrointestinal tract might allow their simultaneous utilization. Complex networks of cross-feeding between bacteria exist in the gastrointestinal niche, and these substrates are probably released into the gut by the concerted action of different microbial enzymes on glycoproteins and other glycoconjugates (21, 23, 24, 62). The results presented here describe the first catabolic route for the utilization of 6'-fucosyl-related compounds in bacteria. They support previous works that assign to *N*-glycoproteins a role in nourishing beneficial bacteria in the gut. In addition, they show that commensals and pathogens share related mechanisms to take advantage of host molecules.

## MATERIALS AND METHODS

**Transfucosylation reactions.** The AlfC  $\alpha$ -L-fucosidase was expressed and purified as previously described (45). The transfucosylation activity of 6 $\times$ His-AlfC was also analyzed as previously indicated (47), with some modifications. The reaction mixtures (1 ml) contained 100 mM Tris-HCl buffer (pH 7.0); 50 mM *p*-nitrophenyl- $\alpha$ -L-fucopyranoside (*p*NP-fuc) as the donor; and GlcNAc-Asn (100 mM), *N,N'*-diacetylchitobiose (150 mM), galactose (150 mM), or glucose (150 mM) as the acceptor. The mixtures were heated at 98°C to solubilize *p*NP-fuc and then cooled to 42°C. Reactions were started by adding 800 U/ml AlfC, and after 20 min (reaction with GlcNAc-Asn as an acceptor), 15 min (reaction with galactose as an acceptor), and 10 min (reactions with *N,N'*-diacetylchitobiose or glucose as an acceptor), they were heated at 98°C for 3 min to stop the reaction. The maximum yields obtained for 6'FN-Asn, N2F *N*-glycan, 6'FucGal, and 6'FucGlc were 3.6 g/liter, 1.8 g/liter, 1.3 g/liter, and 3.3 g/liter, respectively. One-dimensional (1D)  $^1\text{H}$  and two-dimensional (2D)  $^1\text{H}$  and  $^{13}\text{C}$  heteronuclear single quantum coherence (HSQC) and 2D heteronuclear multiple-bond correlation (HMBC) NMR analyses demonstrated the exclusive formation of an  $\alpha$ 1,6-glycosidic linkage between the sugar monomers.

**Analytical and semipreparative HPLC analyses.** Transfucosylation reaction products were purified by high-performance liquid chromatography (HPLC) using a preparative Rezex RCM-monosaccharide column (Phenomenex) as previously described (65). Appropriate fractions were pooled, concentrated, and analyzed by using an analytical Rezex RSO-oligosaccharide column (Phenomenex) in the case of 6'FN-Asn synthesis and an analytical Rezex RCM-monosaccharide column (Phenomenex) in the case of N2F *N*-glycan, 6'FucGal, and 6'FucGlc synthesis. The synthesized compounds 6'FN-Asn, N2F *N*-glycan, 6'FucGal, and 6'FucGlc were subjected to complete hydrolysis with the  $\alpha$ -L-fucosidase AlfC, and the released L-fucose was measured in order to determine their concentrations.

To determine the glycoamino acids and carbohydrates present in the supernatants from the *Lactobacillus* strain cultures, the bacterial cells were removed by centrifugation, and the cultures were analyzed with an ICS3000 chromatographic system (Dionex) using a CarboPac PA100 column with pulsed amperometric detection. A gradient of 10 mM to 100 mM NaOH was used for 16 min at a flow rate of 1 ml/min.

**Nuclear magnetic resonance spectroscopy.** Samples for nuclear magnetic resonance (NMR) spectroscopy were prepared as previously described (66). NMR spectra were also recorded as previously indicated (66), with some modifications.  $^1\text{H}$ - $^{13}\text{C}$  HSQC data were acquired with 360 transients over a spectral width of 10 ppm (for  $^1\text{H}$ ) and 160 to 220 ppm (for  $^{13}\text{C}$ ) and 128 points in the indirect dimension. Total correlation spectroscopy (TOCSY) data were acquired with 64 transients over a spectral width of 10 ppm in both dimensions and 128 points in the indirect dimension. NMR spectra were processed using the program MesReNoeva 8.1 (Mestrelab Research SL).

**Bacterial strains and culture conditions.** *Lactobacillus* strains (Table 1) were grown at 37°C under static conditions in MRS medium (Difco). *Escherichia coli* was used as a cloning host, and it was routinely grown in Luria-Bertani medium (Oxoid) with shaking at 37°C. The corresponding solid media were prepared by adding 1.8% agar. *L. casei* growth assays with different carbon sources were carried out in MRS basal medium as previously described (41). 6'FN-Asn, 6'FucGal, 6'FucGlc, 6'FN, GlcNAc-Asn, GlcNAc, or glucose was added to MRS basal medium at a concentration of 4 mM, and N2F *N*-glycan was added at 2 mM. Bacterial growth was determined in microtiter plates with a POLARstar Omega plate reader (BMG Labtech). At least three independent biological replicates for each growth curve were obtained, and a representative growth curve is shown. For each biological replicate comparing the wild type and a mutant strain, the same batch of MRS basal medium was used. The concentrations of glycoamino acids

**TABLE 1** Strains and plasmids used in this study<sup>a</sup>

Strain or plasmid	Relevant genotype or characteristic(s)	Source or reference
<b>Strains</b>		
<i>Lactobacillus casei</i>		
BL23	Wild type	CECT 5275
BL372	BL23 <i>alfH</i> ::pRV300 Erm <sup>r</sup>	44
BL392	BL23 <i>sugK</i> ::pRV300 Erm <sup>r</sup>	41
BL405	BL23 <i>alfR2</i> (466-bp internal deletion at <i>alfR2</i> )	This work
BL406	BL23 <i>alfR2 alfC</i> (466-bp internal deletion at <i>alfR2</i> and <i>alfC</i> ::pRV300 Erm <sup>r</sup> )	This work
BL407	BL23 <i>alfR2 alfH</i> (466-bp internal deletion at <i>alfR2</i> and frameshift in <i>alfH</i> at the BclI site)	This work
BL415	BL23 <i>alfC</i> ::pRV300 Erm <sup>r</sup>	This work
BL416	BL23 <i>asdA</i> (frameshift at the HindIII site)	This work
BL417	BL23 <i>pepV</i> (frameshift at the NcoI site)	This work
BL418	BL23 <i>asnA2</i> (frameshift at the BclI site)	This work
<i>Escherichia coli</i>		
DH10B	F <sup>-</sup> <i>endA1 recA1 galE15 galk16 nupG rpsL ΔlacX74 φ80lacZΔM15 araD139 Δ(ara leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ<sup>-</sup></i>	Invitrogen
GM119	F <sup>-</sup> <i>supE44 lacY1 galk2 galT22 metB1 dcm-6 dam-3 tsx-78 λ<sup>-</sup></i>	ATCC 53339
BE50	BL21(DE3) containing pREPGroES/GroEL	80
PE149	DH10B containing pQEalfc	45
PE173	BE50 containing pQEasnA2	This work
PE174	BL21(DE3)/pLys containing pETasdA	This work
PE176	BE50 containing pQEsugK	This work
<b>Plasmids</b>		
pRV300	Suicide vector carrying Erm <sup>r</sup> from pAMβ1	68
pRValfR2	pRV300 with a fragment carrying a 466-bp deletion at the <i>alfR2</i> coding region	This work
pRVasdA	pRV300 with a frameshift at the HindIII site in the <i>asdA</i> fragment	This work
pRVpepV	pRV300 with a frameshift at the NcoI site in the <i>pepV</i> fragment	This work
pRVasnA	pRV300 with a frameshift at the BclI site in the <i>asnA</i> fragment	This work
pRValfC	pRV300 with a 669-bp <i>alfC</i> fragment	This work
pRValfH	pRV300 with a frameshift at the BclI site in the <i>alfH</i> fragment	This work
pQE80	<i>E. coli</i> expression vector; Amp <sup>r</sup>	Qiagen
pET-28a(+)	<i>E. coli</i> expression vector; Kan <sup>r</sup>	Novagen
pQEasnA2	pQE80 containing the <i>asnA2</i> coding region	This work
pETasdA	pET-28a(+)	This work
pQEsugK	pQE80 containing the <i>sugK</i> coding region	This work

<sup>a</sup>CECT, Colección Española de Cultivos Tipo; Erm<sup>r</sup>, erythromycin resistant; Amp<sup>r</sup>, ampicillin resistant; Kan<sup>r</sup>, kanamycin resistant.

and carbohydrates in the culture supernatants at the end of fermentation were determined by HPLC as described above.

*E. coli* strains were transformed by electroporation with a Gene Pulser apparatus (Bio-Rad), as recommended by the manufacturer. *E. coli* DH10B transformants were selected with ampicillin (100 μg/ml), and *E. coli* BE50 transformants were selected with ampicillin (100 μg/ml) and kanamycin (50 μg/ml). *L. casei* strains were transformed as described previously (67). *L. casei* transformants were selected with erythromycin (5 μg/ml).

**Construction of *L. casei* mutants in *alf-2* genes.** *L. casei* BL23 chromosomal DNA was isolated as previously described (67) and used as the template for PCRs, which were performed with the Expand high-fidelity PCR system (Roche). The *alfR2* gene was amplified by PCR using the primer pair AspDecaFor/XhoPeptVRev2 (see Table S3 in the supplemental material). The resulting 1,289-bp fragment was ligated into pRV300 (68) digested previously with EcoRV/KpnI and treated with the Klenow fragment of DNA polymerase I. The obtained plasmid was digested with Sall, ligated, and transformed. A clone with a 466-bp deletion in *alfR2* (pRValfR2) was selected. DNA fragments containing parts of *asdA*, *pepV*, and *asnA2* were obtained by PCR using the oligonucleotides pairs AsdFor/AsdRev, PepVFor/PepVRev, and AsnFor/AsnRev, respectively (Table S3), and cloned into pRV300 digested with EcoRV. The resulting plasmids, pRVasdA, pRVpepV, and pRVasnA, were cleaved at the unique HindIII, NcoI, and BclI restriction sites present in the *asdA*, *pepV*, and *asnA2* coding regions, respectively, to introduce frameshifts into their corresponding coding sequences (Table 1). The three digested plasmids were then treated with Klenow fragment, ligated, and transformed into *E. coli* DH10B. The resulting plasmids were transformed into *L. casei* BL23, and frameshifts were introduced into the corresponding genes by a double-recombination strategy (41) (Table 1). To construct an *alfC* mutant, an internal DNA fragment of *alfC* was obtained by PCR using the oligonucleotides AlfCFor and AlfCRev. The PCR product was cloned into pRV300 digested with EcoRV. The resulting plasmid, pRValfC, was used to transform *L. casei* BL23, and single-crossover integrants were selected by resistance to erythromycin and confirmed by PCR analysis and DNA sequencing. One mutant was selected and named BL415. The same procedure was used to inactivate *alfC* in the mutant strain BL405 (*alfR2*), obtaining the *alfR2 alfC* double mutant (strain BL406). To construct the *alfR2 alfH* double mutant (strain BL407), the plasmid pRValfH was generated (Table 1). A DNA fragment

containing part of *alfH* was obtained with the oligonucleotide pair FucPerFor/FucPerRev and cloned into pRV300 digested with EcoRV. The resulting plasmid, pRValfH, was cleaved at the unique BclI restriction site present in the *alfH* coding region, treated with Klenow fragment, ligated, and transformed. A construct in which a frameshift was introduced at the BclI site in *alfH* (pRValfH) was selected. pRValfH was transformed into the mutant strain BL405 (*alfR2*). A clone having a second recombination event was selected to obtain the *alfR2 alfH* double mutant (strain BL407).

**Sequence analysis.** DNA sequencing was carried out by the Central Service of Research Support of the University of Valencia (Spain). M13 universal and reverse primers or custom primers hybridizing within the appropriate DNA fragments were used for sequencing. Sequence analyses were carried out with DNAMAN 4.03 for Windows (Lynnon BioSoft), and sequence similarities were analyzed with the BLAST program (69). Genomic context analysis was performed at the Microbial Genome Database for Comparative Analysis (MBGD) (<http://mbgd.genome.ad.jp/>) (70).

**Reverse transcription-quantitative PCR analysis.** Total RNA was isolated from *L. casei* strains BL23 (WT) and BL405 (*alfR2*) grown in MRS basal medium supplemented with 4 mM different glycans (6'FN-Asn, 6'FN, GlcNAc, or glucose), as previously described (41). The isolated RNA was digested with DNase I and retrotranscribed using the Maxima first-strand cDNA synthesis kit (Fermentas) (41). Reverse transcription-quantitative PCR (RT-qPCR) was performed for each cDNA sample in triplicate using the LightCycler 480 system (Roche), LC fast-start DNA master SYBR green I (Roche), and the primers pairs q29280for/q29280rev (*sugK*), q29290for/q29290rev (*asnA2*), q29300for/q29300rev (*pepV*), q29310for/q29310rev (*alfR2*), q29320for/q29320rev (*asdA*), q29330for/q29330rev (*alfH*), and q29340for/q29340rev (*alfC*) (Table S3). The reaction mixtures and cycling conditions were previously described (41). The *pyrG*, *lepA*, and *ileS* genes were chosen as reference genes (71). Relative expression values were calculated using the software tool REST (relative expression software tool) (72). Linearity and amplification efficiency were determined for each primer pair.

**Expression and purification of AsnA2, AsdA, and SugK.** The coding regions of *asnA2*, *asdA*, and *sugK* were amplified by PCR using the primer pairs AsnHindIIIFor/AsnBamHIRev, AsdAHCt-F/AsdAHCt-R, and SugKBamHIFor/SugKRev, respectively (Table S3). *AsnA2* was cloned into the HindIII-BamHI sites and *SugK* was cloned into the BamHI-SmaI sites of the pQE80 vector and transformed into *E. coli* BE50 coexpressing the chaperones *groES* and *groEL*. pETasdA was constructed using the Gibson assembly kit (NEB) with the *asdA* PCR fragment and pET28a(+) digested with NcoI and XhoI. pETasdA was transformed into *E. coli* BL21(DE3)/pLys. For purification, cells were grown to an OD at 600 nm ( $OD_{600}$ ) of 0.8, 1 mM isopropyl- $\beta$ -D-thiogalactopyranoside was added, and incubation was continued at 25°C for 10 h. Bacterial cell extracts were loaded onto a HisTrap column (GE Healthcare), and His-tagged protein was purified according to the supplier's recommendations. The native molecular weight of the *AsnA2* protein was estimated by size exclusion chromatography (HiPrep 16/60 Sephacryl S-300 HR column).

**Mass spectrometry analysis.** Protein bands from *AsnA2* purification were excised from the gel, trypsinized, and analyzed with a 5800 matrix-assisted laser desorption ionization–tandem time of flight (MALDI-TOF/TOF) system (AB Sciex) at the proteomics service of the University of Valencia. MS and tandem MS (MS/MS) data were analyzed with the Mascot server.

**AsnA2 enzyme activity.** The activity of the purified *AsnA2* enzyme was assayed at 37°C with GlcNAc-Asn and 6'FN-Asn as the substrates. The released GlcNAc and 6'FN, respectively, were quantified by analyzing the reaction mixtures by ionic chromatography (Dionex) as described above. Reactions using mixtures (20  $\mu$ l) containing 5 mM the substrate in 100 mM Tris-HCl buffer (pH 7.0) were initiated by adding 0.2  $\mu$ g of the enzyme. Protein deglycosylation assays were performed with reaction mixtures (15  $\mu$ l) containing 3.75  $\mu$ g of ovalbumin or lactoferrin in 100 mM Tris-HCl buffer (pH 7.0). The reactions were initiated with 0.2  $\mu$ g of the enzyme, and the mixtures were incubated at 37°C overnight.

**AsdA enzyme activity.** *AsdA* decarboxylase activity on L-Asp was measured as previously described, with some modifications (73). The resulting L-Ala was detected by using a coupled enzyme assay. Reactions using mixtures (100  $\mu$ l) containing 100 mM K-acetate buffer (pH 5.5), 0.2 mM pyridoxal 5-phosphate, 1 mM  $\alpha$ -ketoglutarate, 0.4 mM NAD<sup>+</sup>, 0.32 U of L-alanine dehydrogenase (Sigma), and 10  $\mu$ g of *AsdA* were initiated by the addition of 40 mM L-Asp. Reaction mixtures were incubated for 60 min at 37°C, and the production of NADH was monitored at 340 nm.

**SugK enzyme activity.** *SugK* phosphorylation activity on different sugars was determined by using a coupled enzyme assay as previously described (74). Reactions using mixtures (100  $\mu$ l) containing 100 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 5 mM ATP, 1 mM phosphoenolpyruvate, 0.2 mM NADH, 10 U of pyruvate kinase, 7 U of lactate dehydrogenase, and various substrates (GlcNAc, Glc, Gal, or GalNAc) at a final concentration of 1 mM were initiated by the addition of 0.75  $\mu$ g of *SugK*. Reaction mixtures were incubated for 15 min at 37°C, and NADH formation was monitored at 340 nm.

**Phylogenetic analysis.** Sequences of *alfC*, *alfH*, *asnA2*, *asdA*, and *pepV* homologues were retrieved from the microbial genome repository at the NCBI by BLAST (75) using their corresponding *L. casei* BL23 protein sequences as query sequences. For *asnA2*, only sequences from the *Lactobacillaceae* and *Bifidobacteriaceae* were included. Domain analysis was performed using the tools implemented at the NCBI BLAST site (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The resulting data sets were aligned with M-Coffee (76) at the T-Coffee server (<http://tcoffee.org.cat>), with default settings. Positions of uncertain homology and gaps were removed using GBLOCKS (77) at the Gblocks server ([http://molevol.cmima.csic.es/castresana/Gblocks\\_server.html](http://molevol.cmima.csic.es/castresana/Gblocks_server.html)), allowing smaller final blocks and less strict flanking positions. Redundant sequences were removed by using the EMBOSS suite Skipredundant tool (78) with a percent sequence identity redundancy threshold of 98%. The best-fit models of amino acid substitution and maximum likelihood trees were obtained using PhyML version 3.0 (79) at the PhyML

server (<http://www.atgc-montpellier.fr/phyml>). Bootstrap support values were obtained from 1,000 pseudorandom replicates.

**Statistical analysis.** Student's *t* test was performed using Statgraphics Plus version 2.1 (Statistical Graphics Corp., USA), and it was used to detect statistically significant differences between the final OD values reached by *L. casei* BL405 (*alfR2*) cultures and the mutant strains BL406 (*alfR2 alfC*) and BL407 (*alfR2 alfH*). Statistical significance was accepted at a *P* value of <0.05.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**FIG S1**, TIF file, 0.7 MB.

**FIG S2**, TIF file, 1.6 MB.

**FIG S3**, TIF file, 0.8 MB.

**FIG S4**, TIF file, 0.7 MB.

**FIG S5**, TIF file, 1 MB.

**FIG S6**, TIF file, 1 MB.

**TABLE S1**, DOCX file, 0.02 MB.

**TABLE S2**, DOCX file, 0.02 MB.

**TABLE S3**, DOCX file, 0.01 MB.

## ACKNOWLEDGMENTS

This work was financed by funds of the Spanish Ministry for Economy and Competitiveness (MINECO)/FEDER through projects AGL2014-52996-C2 (1-R and 2-R) and AGL2017-84165-C2 (1-R and 2-R). J.E.B. was supported by a Santiago Grisolia predoctoral fellowship from the Valencian Government. J.R.-D. was supported by a Ramon y Cajal contract by the Spanish Ministry for Economy and Competitiveness. R.G.-R. was the recipient of a postdoctoral fellowship from the Generalitat Valenciana that was cofounded by the European Social Fund. Part of the equipment employed in this work has been funded by the Generalitat Valenciana and cofinanced with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020).

## REFERENCES

- Chen W, Liu F, Ling Z, Tong X, Xiang C. 2012. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS One* 7:e39743. <https://doi.org/10.1371/journal.pone.0039743>.
- Chen SJ, Liu XW, Liu JP, Yang XY, Lu FG. 2014. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. *World J Gastroenterol* 20:9468–9475. <https://doi.org/10.3748/wjg.v20.i28.9468>.
- Blander JM, Longman RS, Iliiev ID, Sonnenberg GF, Artis D. 2017. Regulation of inflammation by microbiota interactions with the host. *Nat Immunol* 18:851–860. <https://doi.org/10.1038/ni.3780>.
- Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. 2009. Probiotic effects on cold and influenza-like symptom incidence and duration in children. *Pediatrics* 124:e172–e179. <https://doi.org/10.1542/peds.2008-2666>.
- Tokuhara D, Kurashima Y, Kamioka M, Nakayama T, Ernst P, Kiyono H. 2019. A comprehensive understanding of the gut mucosal immune system in allergic inflammation. *Allergol Int* 68:17–25. <https://doi.org/10.1016/j.alit.2018.09.004>.
- Thursby E, Juge N. 2017. Introduction to the human gut microbiota. *Biochem J* 474:1823–1836. <https://doi.org/10.1042/BCJ20160510>.
- Apweiler R, Hermjakob H, Sharon N. 1999. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. *Biochim Biophys Acta* 1473:4–8. [https://doi.org/10.1016/s0304-4165\(99\)00165-8](https://doi.org/10.1016/s0304-4165(99)00165-8).
- Krasnova L, Wong CH. 2016. Exploring human glycosylation for better therapies. *Mol Aspects Med* 51:125–143. <https://doi.org/10.1016/j.mam.2016.05.003>.
- Park D, Xu G, Barboza M, Shah IM, Wong M, Raybould H, Mills DA, Lebrilla CB. 2017. Enterocyte glycosylation is responsive to changes in extracellular conditions: implications for membrane functions. *Glycobiology* 27:847–860. <https://doi.org/10.1093/glycob/cwx041>.
- Picariello G, Ferranti P, Mamone G, Roepstorff P, Addeo F. 2008. Identification of N-linked glycoproteins in human milk by hydrophilic interaction liquid chromatography and mass spectrometry. *Proteomics* 8:3833–3847. <https://doi.org/10.1002/pmic.200701057>.
- Yang Y, Zheng N, Zhao X, Zhang Y, Han R, Zhao S, Yang J, Li S, Guo T, Zang C, Wang J. 2017. N-glycosylation proteomic characterization and cross-species comparison of milk whey proteins from dairy animals. *Proteomics* 17:1600434. <https://doi.org/10.1002/pmic.201600434>.
- Imperiali B, Hendrickson TL. 1995. Asparagine-linked glycosylation: specificity and function of oligosaccharyl transferase. *Bioorg Med Chem* 3:1565–1578. [https://doi.org/10.1016/0968-0896\(95\)00142-5](https://doi.org/10.1016/0968-0896(95)00142-5).
- Ohtsubo K, Marth JD. 2006. Glycosylation in cellular mechanisms of health and disease. *Cell* 126:855–867. <https://doi.org/10.1016/j.cell.2006.08.019>.
- Lyons JJ, Milner JD, Rosenzweig SD. 2015. Glycans instructing immunity: the emerging role of altered glycosylation in clinical immunology. *Front Pediatr* 3:54. <https://doi.org/10.3389/fped.2015.00054>.
- Mathias A, Corthesy B. 2011. Recognition of gram-positive intestinal bacteria by hybridoma- and colostrum-derived secretory immunoglobulin A is mediated by carbohydrates. *J Biol Chem* 286:17239–17247. <https://doi.org/10.1074/jbc.M110.209015>.
- Zuniga M, Monedero V, Yebra MJ. 2018. Utilization of host-derived glycans by intestinal *Lactobacillus* and *Bifidobacterium* species. *Front Microbiol* 9:1917. <https://doi.org/10.3389/fmicb.2018.01917>.
- Koropatkin NM, Cameron EA, Martens EC. 2012. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol* 10:323–335. <https://doi.org/10.1038/nrmicro2746>.
- Fairbanks AJ. 2017. The ENGases: versatile biocatalysts for the production of homogeneous N-linked glycopeptides and glycoproteins. *Chem Soc Rev* 46:5128–5146. <https://doi.org/10.1039/c6cs00897f>.
- Collin M, Shannon O, Bjorck L. 2008. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. *Proc Natl Acad Sci U S A* 105:4265–4270. <https://doi.org/10.1073/pnas.0711271105>.
- Renzi F, Manfredi P, Mally M, Moes S, Jenö P, Cornelis GR. 2011. The N-glycan glycoprotein deglycosylation complex (Gpd) from *Capnocy-*



- tophaga animorsus* deglycosylates human IgG. PLoS Pathog 7:e1002118. <https://doi.org/10.1371/journal.ppat.1002118>.
21. Garbe J, Sjögren J, Cosgrave EF, Struwe WB, Bober M, Olin AI, Rudd PM, Collin M. 2014. EndoE from *Enterococcus faecalis* hydrolyzes the glycans of the biofilm inhibiting protein lactoferrin and mediates growth. PLoS One 9:e91035. <https://doi.org/10.1371/journal.pone.0091035>.
  22. Robb M, Hobbs JK, Woodiga SA, Shapiro-Ward S, Suits MD, McGregor N, Brumer H, Yesilkaya H, King SJ, Boraston AB. 2017. Molecular characterization of N-glycan degradation and transport in *Streptococcus pneumoniae* and its contribution to virulence. PLoS Pathog 13:e1006090. <https://doi.org/10.1371/journal.ppat.1006090>.
  23. Garrido D, Nwosu C, Ruiz-Moyano S, Aldredge D, German JB, Lebrilla CB, Mills DA. 2012. Endo-beta-N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins. Mol Cell Proteomics 11:775–785. <https://doi.org/10.1074/mcp.M112.018119>.
  24. Parc AL, Karav S, De Moura Bell J, Frese SA, Liu Y, Mills DA, Block DE, Barile D. 2015. A novel endo-beta-N-acetylglucosaminidase releases specific N-glycans depending on different reaction conditions. Biotechnol Prog 31:1323–1330. <https://doi.org/10.1002/btpr.2133>.
  25. Li M, Bai Y, Zhou J, Huang W, Yan J, Tao J, Fan Q, Liu Y, Mei D, Yan Q, Yuan J, Malard P, Wang Z, Gu J, Taniguchi N, Li W. 2019. Core fucosylation of maternal milk N-glycan evokes B cell activation by selectively promoting the L-fucose metabolism of gut Bifidobacterium spp. and Lactobacillus spp. mBio 10:e00128-19. <https://doi.org/10.1128/mBio.00128-19>.
  26. Wang Y, Guo HC. 2010. Crystallographic snapshot of glycosylasparaginase precursor poised for autoprocessing. J Mol Biol 403:120–130. <https://doi.org/10.1016/j.jmb.2010.08.038>.
  27. Witte MD, van der Marel GA, Aerts JM, Overkleef HS. 2011. Irreversible inhibitors and activity-based probes as research tools in chemical glycobiology. Org Biomol Chem 9:5908–5926. <https://doi.org/10.1039/c1ob05531c>.
  28. Fan JQ, Lee YC. 1997. Detailed studies on substrate structure requirements of glycoamidases A and F. J Biol Chem 272:27058–27064. <https://doi.org/10.1074/jbc.272.43.27058>.
  29. Riskey JM, Huang DH, Kaylor JJ, Malik JJ, Xia YQ, York WM. 2001. Glycosylasparaginase activity requires the alpha-carboxyl group, but not the alpha-amino group, on N(4)-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparagine. Arch Biochem Biophys 391:165–170. <https://doi.org/10.1006/abbi.2001.2416>.
  30. Tarentino AL, Plummer TH, Jr. 1993. The first demonstration of a prokaryotic glycosylasparaginase. Biochem Biophys Res Commun 197:179–186. <https://doi.org/10.1006/bbrc.1993.2457>.
  31. Sun G, Yu X, Bao C, Wang L, Li M, Gan J, Qu D, Ma J, Chen L. 2015. Identification and characterization of a novel prokaryotic peptide:N-glycosidase from *Elizabethkingia meningoseptica*. J Biol Chem 290:7452–7462. <https://doi.org/10.1074/jbc.M114.605493>.
  32. Wang T, Cai ZP, Gu XQ, Ma HY, Du YM, Huang K, Voglmeir J, Liu L. 2014. Discovery and characterization of a novel extremely acidic bacterial N-glycanase with combined advantages of PNGase F and A. Biosci Rep 34:e00149. <https://doi.org/10.1042/BSR20140148>.
  33. Guo HC, Xu Q, Buckley D, Guan C. 1998. Crystal structures of Flavobacterium glycosylasparaginase. An N-terminal nucleophile hydrolase activated by intramolecular proteolysis. J Biol Chem 273:20205–20212. <https://doi.org/10.1074/jbc.273.32.20205>.
  34. Tarentino AL, Quinones G, Hauer CR, Changchien LM, Plummer TH, Jr. 1995. Molecular cloning and sequence analysis of *Flavobacterium meningosepticum* glycosylasparaginase: a single gene encodes the alpha and beta subunits. Arch Biochem Biophys 316:399–406. <https://doi.org/10.1006/abbi.1995.1053>.
  35. Tuohy KM, Pinart-Gilberga M, Jones M, Hoyles L, McCartney AL, Gibson GR. 2007. Survivability of a probiotic *Lactobacillus casei* in the gastrointestinal tract of healthy human volunteers and its impact on the faecal microflora. J Appl Microbiol 102:1026–1032. <https://doi.org/10.1111/j.1365-2672.2006.03154.x>.
  36. Radicioni M, Koirala R, Fiore W, Leuratti C, Guglielmetti S, Arioli S. 2019. Survival of *L. casei* DG (*Lactobacillus paracasei* CNCM11572) in the gastrointestinal tract of a healthy paediatric population. Eur J Nutr 58:3161–3170. <https://doi.org/10.1007/s00394-018-1860-5>.
  37. Rubio R, Jofre A, Martin B, Aymerich T, Garriga M. 2014. Characterization of lactic acid bacteria isolated from infant faeces as potential probiotic starter cultures for fermented sausages. Food Microbiol 38:303–311. <https://doi.org/10.1016/j.fm.2013.07.015>.
  38. Mansour NM, Heine H, Abdou SM, Shenana ME, Zakaria MK, El-Diwanly A. 2014. Isolation of *Enterococcus faecium* NM113, *Enterococcus faecium* NM213 and *Lactobacillus casei* NM512 as novel probiotics with immunomodulatory properties. Microbiol Immunol 58:559–569. <https://doi.org/10.1111/1348-0421.12187>.
  39. Hill D, Sugrue I, Tobin C, Hill C, Stanton C, Ross RP. 2018. The *Lactobacillus casei* group: history and health related applications. Front Microbiol 9:2107. <https://doi.org/10.3389/fmicb.2018.02107>.
  40. McFarland LV, Evans CT, Goldstein EJC. 2018. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med (Lausanne) 5:124. <https://doi.org/10.3389/fmed.2018.00124>.
  41. Bidart GN, Rodríguez-Díaz J, Monedero V, Yebra MJ. 2014. A unique gene cluster for the utilization of the mucosal and human milk-associated glycans galacto-N-biose and lacto-N-biose in *Lactobacillus casei*. Mol Microbiol 93:521–538. <https://doi.org/10.1111/mmi.12678>.
  42. Bidart GN, Rodríguez-Díaz J, Pérez-Martínez G, Yebra MJ. 2018. The lactose operon from *Lactobacillus casei* is involved in the transport and metabolism of the human milk oligosaccharide core-2 N-acetylglucosamine. Sci Rep 8:7152. <https://doi.org/10.1038/s41598-018-25660-w>.
  43. Bidart GN, Rodríguez-Díaz J, Yebra MJ. 2016. The extracellular wall-bound  $\beta$ -N-acetylglucosaminidase from *Lactobacillus casei* is involved in the metabolism of the human milk oligosaccharide lacto-N-triose. Appl Environ Microbiol 82:570–577. <https://doi.org/10.1128/AEM.02888-15>.
  44. Rodríguez-Díaz J, Rubio-del-Campo A, Yebra MJ. 2012. *Lactobacillus casei* ferments the N-acetylglucosamine moiety of fucosyl- $\alpha$ -1,3-N-acetylglucosamine and excretes L-fucose. Appl Environ Microbiol 78:4613–4619. <https://doi.org/10.1128/AEM.00474-12>.
  45. Rodríguez-Díaz J, Monedero V, Yebra MJ. 2011. Utilization of natural fucosylated oligosaccharides by three novel  $\alpha$ -L-fucosidases from a probiotic *Lactobacillus casei* strain. Appl Environ Microbiol 77:703–705. <https://doi.org/10.1128/AEM.01906-10>.
  46. Maze A, Boel G, Zuniga M, Bourand A, Loux V, Yebra MJ, Monedero V, Correia K, Jacques N, Beauflis S, Poncet S, Joyet P, Milohanic E, Casaregola S, Auffray Y, Perez-Martinez G, Gibrat JF, Zagorec M, Francke C, Hartke A, Deutscher J. 2010. Complete genome sequence of the probiotic *Lactobacillus casei* strain BL23. J Bacteriol 192:2647–2648. <https://doi.org/10.1128/JB.00076-10>.
  47. Rodríguez-Díaz J, Carbajo RJ, Pineda-Lucena A, Monedero V, Yebra MJ. 2013. Synthesis of fucosyl-N-acetylglucosamine disaccharides by trans-fucosylation using  $\alpha$ -L-fucosidases from *Lactobacillus casei*. Appl Environ Microbiol 79:3847–3850. <https://doi.org/10.1128/AEM.00229-13>.
  48. Noronkoski T, Mononen I. 1997. Influence of L-fucose attached alpha 1→6 to the asparagine-linked N-acetylglucosamine on the hydrolysis of the N-glycosidic linkage by human glycosylasparaginase. Glycobiology 7:217–220. <https://doi.org/10.1093/glycob/7.2.217>.
  49. Makino M, Kojima T, Ohgushi T, Yamashina I. 1968. Studies on enzymes acting on glycopeptides. J Biochem 63:186–192. <https://doi.org/10.1093/oxfordjournals.jbchem.a128760>.
  50. Aronson NN, Jr. 1999. Aspartylglycosaminuria: biochemistry and molecular biology. Biochim Biophys Acta 1455:139–154. [https://doi.org/10.1016/S0925-4439\(99\)00076-9](https://doi.org/10.1016/S0925-4439(99)00076-9).
  51. Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX. 2018. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A 115:12023–12027. <https://doi.org/10.1073/pnas.1812833115>.
  52. Froehlich JW, Dodds ED, Barboza M, McJimpsey EL, Seipert RR, Francis J, An HJ, Freeman S, German JB, Lebrilla CB. 2010. Glycoprotein expression in human milk during lactation. J Agric Food Chem 58:6440–6448. <https://doi.org/10.1021/jf100112x>.
  53. Holscher HD. 2017. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 8:172–184. <https://doi.org/10.1080/19490976.2017.1290756>.
  54. Kashket ER. 1987. Bioenergetics of lactic acid bacteria: cytoplasmic pH and osmotolerance. FEMS Microbiol Rev 46:233–244. [https://doi.org/10.1016/0378-1097\(87\)90110-8](https://doi.org/10.1016/0378-1097(87)90110-8).
  55. Killer J, Kopecny J, Mrazek J, Koppova I, Havlik J, Benada O, Kott T. 2011. *Bifidobacterium actinocoloniiforme* sp. nov. and *Bifidobacterium bohemicum* sp. nov., from the bumblebee digestive tract. Int J Syst Evol Microbiol 61:1315–1321. <https://doi.org/10.1099/ijs.0.022525-0>.
  56. Scardovi V, Trovatelli LD. 1969. New species of bifid bacteria from *Apis mellifica* L. and *Apis indica* F. A contribution to the taxonomy and biochemistry of the genus *Bifidobacterium*. Zentralbl Bakteriell Parasitenkd Infektionskr Hyg 123:64–88.

57. Alberoni D, Gaggia F, Baffoni L, Modesto MM, Biavati B, Di Gioia D. 2019. *Bifidobacterium xylocopae* sp. nov. and *Bifidobacterium aemilianum* sp. nov., from the carpenter bee (*Xylocopa violacea*) digestive tract. *Syst Appl Microbiol* 42:205–216. <https://doi.org/10.1016/j.syapm.2018.11.005>.
58. Olofsson TC, Alsterfjord M, Nilson B, Butler E, Vasquez A. 2014. *Lactobacillus apinorum* sp. nov., *Lactobacillus mellifer* sp. nov., *Lactobacillus mellis* sp. nov., *Lactobacillus melliventris* sp. nov., *Lactobacillus kimbladii* sp. nov., *Lactobacillus helsingborgensis* sp. nov. and *Lactobacillus kullaber-gensis* sp. nov., isolated from the honey stomach of the honeybee *Apis mellifera*. *Int J Syst Evol Microbiol* 64:3109–3119. <https://doi.org/10.1099/ijs.0.059600-0>.
59. Killer J, Votavova A, Valterova I, Vlkova E, Rada V, Hroncova Z. 2014. *Lactobacillus bombi* sp. nov., from the digestive tract of laboratory-reared bumblebee queens (*Bombus terrestris*). *Int J Syst Evol Microbiol* 64:2611–2617. <https://doi.org/10.1099/ijs.0.063602-0>.
60. Vinay-Lara E, Hamilton JJ, Stahl B, Broadbent JR, Reed JL, Steele JL. 2014. Genome-scale reconstruction of metabolic networks of *Lactobacillus casei* ATCC 334 and 12A. *PLoS One* 9:e110785. <https://doi.org/10.1371/journal.pone.0110785>.
61. Arvio M, Mononen I. 2016. Aspartylglycosaminuria: a review. *Orphanet J Rare Dis* 11:162. <https://doi.org/10.1186/s13023-016-0544-6>.
62. Carroll IM, Maharshak N. 2013. Enteric bacterial proteases in inflammatory bowel disease—pathophysiology and clinical implications. *World J Gastroenterol* 19:7531–7543. <https://doi.org/10.3748/wjg.v19.i43.7531>.
63. Altmann F, Schweiszer S, Weber C. 1995. Kinetic comparison of peptide: N-glycosidases F and A reveals several differences in substrate specificity. *Glycoconj J* 12:84–93. <https://doi.org/10.1007/bf00731873>.
64. Li C, Zhu S, Ma C, Wang LX. 2017. Designer alpha1,6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins. *J Am Chem Soc* 139:15074–15087. <https://doi.org/10.1021/jacs.7b07906>.
65. Becerra JE, Coll-Marqués JM, Rodríguez-Díaz J, Monedero V, Yebra MJ. 2015. Preparative scale purification of fucosyl-N-acetylglucosamine disaccharides and their evaluation as potential prebiotics and antiadhesins. *Appl Microbiol Biotechnol* 99:7165–7176. <https://doi.org/10.1007/s00253-015-6666-2>.
66. Bidart GN, Rodríguez-Díaz J, Palomino-Schätzlein M, Monedero V, Yebra MJ. 2017. Human milk and mucosal lacto- and galacto-N-biose synthesis by transgalactosylation and their prebiotic potential in *Lactobacillus* species. *Appl Microbiol Biotechnol* 101:205–215. <https://doi.org/10.1007/s00253-016-7882-0>.
67. Posno M, Leer RJ, van Luijk N, van Giezen MJ, Heuvelmans PT, Lokman BC, Pouwels PH. 1991. Incompatibility of *Lactobacillus* vectors with replicons derived from small cryptic *Lactobacillus* plasmids and segregational instability of the introduced vectors. *Appl Environ Microbiol* 57:1822–1828.
68. Leloup L, Ehrlich SD, Zagorec M, Morel-Deville F. 1997. Single-crossover integration in the *Lactobacillus sake* chromosome and insertional inactivation of the *ptsI* and *lacL* genes. *Appl Environ Microbiol* 63:2117–2123.
69. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403–410. [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2).
70. Uchiyama I, Higuchi T, Kawai M. 2010. MGD update 2010: toward a comprehensive resource for exploring microbial genome diversity. *Nucleic Acids Res* 38:D361–D365. <https://doi.org/10.1093/nar/gkp948>.
71. Landete JM, García-Haro L, Blasco A, Manzanares P, Berbegal C, Monedero V, Zúñiga M. 2010. Requirement of the *Lactobacillus casei* MaeKR two-component system for L-malic acid utilization via a malic enzyme pathway. *Appl Environ Microbiol* 76:84–95. <https://doi.org/10.1128/AEM.02145-09>.
72. Pfaffl MW, Horgan GW, Dempfle L. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* 30:e36. <https://doi.org/10.1093/nar/30.9.e36>.
73. Wang NC, Lee CY. 2006. Molecular cloning of the aspartate 4-decarboxylase gene from *Pseudomonas* sp. ATCC 19121 and characterization of the bifunctional recombinant enzyme. *Appl Microbiol Biotechnol* 73:339–348. <https://doi.org/10.1007/s00253-006-0475-6>.
74. Reith J, Berking A, Mayer C. 2011. Characterization of an N-acetylmuramic acid/N-acetylglucosamine kinase of *Clostridium acetobutylicum*. *J Bacteriol* 193:5386–5392. <https://doi.org/10.1128/JB.05514-11>.
75. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25:3389–3402. <https://doi.org/10.1093/nar/25.17.3389>.
76. Notredame C, Higgins DG, Heringa J. 2000. T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J Mol Biol* 302:205–217. <https://doi.org/10.1006/jmbi.2000.4042>.
77. Castresana J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol Biol Evol* 17:540–552. <https://doi.org/10.1093/oxfordjournals.molbev.a026334>.
78. Rice P, Longden I, Bleasby A. 2000. EMBOSS: the European Molecular Biology Open Software Suite. *Trends Genet* 16:276–277. [https://doi.org/10.1016/s0168-9525\(00\)02024-2](https://doi.org/10.1016/s0168-9525(00)02024-2).
79. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. *Syst Biol* 52:696–704. <https://doi.org/10.1080/10635150390235520>.
80. Dale GE, Schonfeld HJ, Langen H, Stieger M. 1994. Increased solubility of trimethoprim-resistant type S1 DHFR from *Staphylococcus aureus* in *Escherichia coli* cells overproducing the chaperonins GroEL and GroES. *Protein Eng* 7:925–931. <https://doi.org/10.1093/protein/7.7.925>.